PTC Confident About Commercial Prospects For Gene Therapy Upstaza
One-Time Injection Gets CHMP Nod For AADC Deficiency
Executive Summary
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.